“Pyridopyridazine”: A Versatile Nucleus in Pharmaceutical Field
Mohamed A. Ibrahim1,2,3, Ahmed H. Elmenoufy4,5, Mohamed Elagawany1,6, Mohammed M. Ghoneim7,8, Alaa Moawad9
1Department of Chemistry, University of Florida, Gainesville, USA.
2Department of Organic Chemistry, College of Pharmacy, Misr University for Science and Technology, 6th of the October City, Egypt.
3Department of Pharmaceutical Chemistry, College of Pharmacy, Almaarefa Colleges for Science and Technology, Riyadh, Saudi Arabia.
4Department of Pharmaceutical Chemistry, College of Pharmacy, Misr University for Science and Technology, 6th of the October City, Egypt.
5Department of Pharmaceutical Engineering, National Research Centre of Nanomedicine, Huazhong University of Science and Technolgy, Wuhan, China.
6Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
7Department of Pharmacognosy, Faculty of Pharmacy, the University of Al-Azhar, Cairo, Egypt.
8Department of Natural products, School of Pharmacy, Almaarefa Colleges for Science and Technology, Riyadh, Saudi Arabia.
9Department of Pharmacognosy, Faculty of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
DOI: 10.4236/jbm.2015.310008   PDF   HTML   XML   2,904 Downloads   3,983 Views   Citations


Pyridopyridazines are an important kind of nitrogen atom containing heterocyclic compounds due to their synthetic and pharmacological versatility. This fused heterocycle system represents a common structural feature for many bioactive compounds showing a variety of pharmacological activities which makes it an attractive scaffold for the design and development of new drugs. This mini review summarizes an updated information described in recent literature, about the most relevant pharmacological properties of pyridopyridazines derivatives.

Share and Cite:

Ibrahim, M. , Elmenoufy, A. , Elagawany, M. , Ghoneim, M. and Moawad, A. (2015) “Pyridopyridazine”: A Versatile Nucleus in Pharmaceutical Field. Journal of Biosciences and Medicines, 3, 59-66. doi: 10.4236/jbm.2015.310008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Sainsbury, M. (2002) Heterocyclic Chemistry, Basic Concepts in Chemistry. Wiley Interscience and Royal Society of Chemistry, Bristol.
[2] Brown, D.J. (2005) 10. Halogenophthalazines (H 178; E 514). Cinnolines and Phthalazines: Supplement II, Volume 64, The Chemistry of Heterocyclic Compounds Series, John Wiley & Sons, Inc., Hoboken, NJ, 203.
[3] Hoffmann, J., Thien, T. and van’Laar, A. (1983) Effects of Intravenous Endralazine in Essential Hypertension. British Journal of Clinical Pharmacology, 16, 39-44.
[4] Meredith, P.A., Elliott, H., McSHARRY, D.R., Kelman, A.W. and Reid, J.L. (1983) The Pharmacokinetics of Endralazine in Essential Hypertensives and in Normotensive Subjects. British Journal of Clinical Pharmacology, 16, 27-32.
[5] Carling, W.R., Castro, P.J.L., Mitchinson, A. and Street, L.J. (2001) Pyrido-Pyridazine Derivatives as Ligands for Gaba Receptors. Pyrido-Pyridazine Derivatives as Ligands for Gaba Receptors. Google Patents.
[6] Gore, P.M., Looker, B.E., Procopiou, P.A. and Vile, S. (2008) Phthalazine and Pyrido[3, 4-D]pyridazine Compounds as H1 Receptor Antagonists. Google Patents.
[7] Pettus, L.H., Tasker, A. and Wu, B. (2013) Pyrido[3,2-d]pyridazine-2(1H)-one Compounds as p38 Modulators and Methods of Use Thereof. Google Patents.
[8] Tynebor, R.M., Chen, M-H., Natarajan, S.R., O’Neill, E.A., Thompson, J.E., Fitzgerald, C.E., et al. (2011) Synthesis and Biological Activity of Pyridopyridazin-6-one p38 MAP Kinase Inhibitors. Part 1. Bioorganic & Medicinal Chemistry Letters, 21, 411-416.
[9] Pakulska, W., Malinowski, Z., Szczesniak, A.K., Czarnecka, E. and Epsztajn, J. (2009) Synthesis and Pharmacological Evaluation of N-(Dimethylamino)ethyl Derivatives of Benzo- and Pyridopyridazinones. Archiv der Pharmazie, 342, 41-47.
[10] Kaizerman. J., Lucas, B., Mcminn, D.L. and Zamboni, R. (2010) Annelated Pyridazines for the Treatment of Tumors Driven by Inappropriate Hedgehog Signalling. Google Patents.
[11] Whilhelm. R., Loe, B., Alvarez, R., Devens, B. and Fong, A. (1995) Pyrido-[2,3-d]pyridazinones as Potent and Selective type IV Phosphodiesterase Inhibitors. 8th RSC-SCI Medicinal Chemistry Symposium, Cambridge, UK, P-32.
[12] Mylari, B.L., Zembrowski, W.J., Beyer, T.A., Aldinger, C.E. and Siegel, T.W. (1992) Orally Active Aldose Reductase Inhibitors: Indazoleacetic, Oxopyridazineacetic, and Oxopyridopyridazineacetic Acid Derivatives. Journal of Medicinal Chemistry, 35, 2155-2162.
[13] Stanasiuk, J. (2005) Investigation on the Synthesis and Properties of 2-(Alkyl, Aryl)-1,4,5-Trioxo-1,2,3,4,5,6-Hexahy-dropyrido[3,4-d]Pyridazine, Derivatives with Potential Biological Activity. Acta Poloniae Pharmaceutica, 63, 420- 421.
[14] Elassar, A.-Z.A. (2004) Synthesis and Antimicrobial Activity of New Polyfunctionally Substituted Pyridines and Their Fused Derivatives. Indian Journal of Chemistry, 43, 1314-1319.
[15] Tynebor, R.M., Chen, M.-H., Natarajan, S.R., O’Neill, E.A., Thompson, J.E., Fitzgerald, C.E., et al. (2012) Synthesis and Biological Activity of Pyridopyridazin-6-One p38α MAP Kinase Inhibitors. Part 2. Bioorganic & Medicinal Chemistry Letters, 22, 5979-5983.
[16] Bishnoi, M. and Premkumar, L.S. (2013) Changes in TRP Channels Expression in Painful Conditions. The Open Pain Journal, 6, 10-22.
[17] Sladowska, H., Stanasiuk, J., Sieklucka-Dziuba, M., Saran, T. and Kleinrok, Z. (1998) Investigations on the Synthesis and Properties of 4-Aminosubstituted 2,6,7-Trimethyl-1,5-Dioxo-1,2,5,6-Tetrahydropyrido[3,4-d]Pyridazines. Il Farmaco, 53, 475-479.
[18] Epsztajn, J., Czarnecka, E., Szczesniak, A., Pakulska, W. and Malinowski, Z. (2009) Benzo-and Pyrido-Pyridazinones with Analgesic and Antiinflammatory Activity. Google Patents.
[19] Nishikawa, K., Shimkawa, H., Inada, Y., Shibouta, Y., Kikuchi, S., Yurugi, S. and Oka, Y. (1976) Structure-Activity Relationships of the Diuretic Activity of Triaza-and Tetraaza-Naphthalene Compounds. Chemical & Pharmaceutical Bulletin, 24, 2057-2077.
[20] Goodacre, S.C. and Hallett, D.J. (2006) Substituted Pyrido-Pyridazine Derivatives Which Enhance Cognition via the GABA-A Receptors. Google Patents.
[21] Mitchinson, A., Blackaby, W.P., Bourrain, S., Carling, R.W. and Lewis, R.T. (2006) Synthesis of Pyrido [2,3-d]Pyridazines and Pyrazino[2,3-d]-Pyridazines—Novel Classes of GABA Receptor Benzodiazepine Binding Site Ligands. Tetrahedron Letters, 47, 2257-2260.
[22] Kurosawa, M. (1995) Role of Thromboxane A2 Synthase Inhibitors in the Treatment of Patients with Bronchial Asthma. Clinical Therapeutics, 17, 2-10.
[23] Dal, P.V., Giovannoni, M.P., Castellana, C., Palacios, J.M., Beleta, J., Doménech, T., et al. (1997) Novel Heterocyclic-Fused Pyridazinones as Potent and Selective Phosphodiesterase IV Inhibitors. Journal of Medicinal Chemistry, 40, 1417-1421.
[24] Zimmet, P., Alberti, K. and Shaw, J. (2001) Global and Societal Implications of the Diabetes Epidemic. Nature, 13, 782-787.
[25] Kakimoto, S. and Tonooka, S. (1967) Antituberculous Compounds. XXV. Some Derivatives of Pyrido [2,3-d] Pyridazine. Bulletin of the Chemical Society of Japan, 40, 153-159.
[26] Cancer. 18 November 2014. http://www.who.int/cancer/en/
[27] Selvakumar, P., Thennarasu, S. and Mandal, A.B. (2014) Synthesis of Novel Pyridopyridazin-3(2H)-One Derivatives and Evaluation of Their Cytotoxic Activity against MCF-7 Cells. International Scholarly Research Notices, 2014, Article ID: 410716.
[28] Rennie, R.P. (2012) Current and Future Challenges in the Development of Antimicrobial Agents. In: Coates, A.R.M., Ed., Antibiotics Resistance, Handbook of Experimental Pharmacology, Vol. 211, Springer-Verlag, Berlin, 45-65.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.